CDKN1A (Ab-145) Antibody

What is CDKN1A and what is its biological significance?

CDKN1A (also known as p21Cip1) is a potent cyclin-dependent kinase inhibitor that plays a critical role in cell cycle regulation. The protein functions by binding to and inhibiting the activity of cyclin-cyclin-dependent kinase2 or cyclin-dependent kinase4 complexes, thereby regulating cell cycle progression at G1 phase . CDKN1A expression is tightly controlled by the tumor suppressor protein p53, through which it mediates p53-dependent cell cycle G1 phase arrest in response to various stress stimuli .

Beyond cell cycle regulation, CDKN1A interacts with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, playing a regulatory role in S phase DNA replication and DNA damage repair . This dual functionality makes CDKN1A a key molecule in cellular stress responses and genomic integrity maintenance. In some experimental models, mice lacking this gene display enhanced tissue regeneration capacity, suggesting additional roles in regenerative processes.

What epitope does the CDKN1A (Ab-145) antibody recognize?

The CDKN1A (Ab-145) antibody specifically recognizes the peptide sequence around amino acids 143-147 (R-Q-T-S-M) derived from human p21Cip1 . This region is significant because it lies near threonine 145 (T145), a key phosphorylation site that regulates CDKN1A localization and function . The antibody is designed to detect endogenous levels of total p21Cip1 protein, regardless of phosphorylation state .

Understanding the specific epitope recognition properties is essential for experimental design, as it determines which conformational states or post-translational modifications of CDKN1A will be detected. The epitope proximity to the T145 phosphorylation site makes this antibody particularly valuable for studies investigating unmodified versus phosphorylated states of CDKN1A.

What are the verified applications for CDKN1A (Ab-145) antibody?

The CDKN1A (Ab-145) antibody has been validated for multiple experimental applications:

The antibody has demonstrated specific detection of endogenous p21Cip1 protein levels in human cell lines . For optimal results in Western blot applications, the antibody is supplied at 1.0mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, with 150mM NaCl, 0.02% sodium azide, and 50% glycerol . This formulation ensures stability during storage and optimal performance in immunodetection applications.

How should researchers design controls when using CDKN1A (Ab-145) antibody?

Proper control implementation is critical for validating CDKN1A (Ab-145) antibody results. An effective experimental design should include:

Positive Controls:

• Known CDKN1A-expressing cell lines (HeLa cells have been verified)

• Recombinant CDKN1A protein standards at known concentrations

• UV-irradiated cells (which typically upregulate CDKN1A expression)

Negative Controls:

• Antibody preincubated with blocking peptide (peptide competition assay)

• Secondary antibody-only controls to assess non-specific binding

• CDKN1A-knockout or knockdown cell lines (when available)

Validation Methods:

• Peptide competition assays have specifically been shown to eliminate the signal in Western blot analysis of extracts from HeLa cells, confirming specificity

• Multiple detection methods should be employed when possible (WB, IF, IHC) to confirm consistent results

Following randomized control design principles, as outlined in experimental research methodology, significantly enhances result reliability and minimizes bias . Remember that proper blinding of examiners to experimental conditions (when applicable) strengthens validity of findings.

What are the methodological considerations for phosphorylation-specific studies of CDKN1A?

When investigating CDKN1A phosphorylation states, particularly at threonine 145 (T145), researchers should consider:

Sample Preparation:

• Phosphatase inhibitors must be included in all extraction buffers

• Rapid sample processing is essential to preserve phosphorylation states

• Cell lysis conditions can significantly impact phosphoprotein detection

Experimental Approach:

• Use phospho-specific antibodies (such as anti-phospho-CDKN1A Thr145) alongside the CDKN1A (Ab-145) antibody

• Consider treatments that modulate phosphorylation, such as PI3K inhibitor LY294002 (20 μM)

• UV radiation (20 J/m²) has been used to induce CDKN1A expression and subsequent phosphorylation

Data Interpretation:

• Changes in CDKN1A localization should be monitored alongside phosphorylation state

• Nuclear versus cytoplasmic fractionation may be necessary to fully understand functional implications

• Quantitative assessment using phospho/total protein ratios provides more robust data than single measurements

Research has demonstrated that activated Akt phosphorylates CDKN1A at threonine 145, leading to cytoplasmic localization of CDKN1A in both HTLV-1-infected and ATLL cell lines . After treatment with LY294002, Akt was dephosphorylated, which consequently led to CDKN1A dephosphorylation at T145 and its relocalization to the nucleus in HTLV-1-infected cell lines .

How does cellular localization of CDKN1A affect its function, and how can this be studied?

The subcellular localization of CDKN1A critically affects its function. Research has revealed distinct activities based on nuclear versus cytoplasmic localization:

Nuclear CDKN1A:

• Primarily functions as a cell cycle inhibitor by interacting with cyclin-CDK complexes

• Participates in DNA damage repair through PCNA interaction

• Mediates p53-dependent cell cycle arrest

Cytoplasmic CDKN1A:

• Often results from phosphorylation at T145 by activated Akt

• May not effectively inhibit cell cycle progression after DNA damage

• Can have altered interactions with binding partners

• May contribute to different cellular outcomes in disease states

Methodological Approaches to Study Localization:

• Immunofluorescence microscopy with CDKN1A (Ab-145) antibody

• Nuclear/cytoplasmic fractionation followed by Western blot analysis

• Co-immunoprecipitation to identify location-specific binding partners

• Treatment with signaling inhibitors like LY294002 to modulate localization

What are the best practices for troubleshooting non-specific binding with CDKN1A (Ab-145) antibody?

When encountering non-specific binding issues with CDKN1A (Ab-145) antibody, consider the following systematic troubleshooting approach:

Common Sources of Non-specific Binding:

• Insufficient blocking

• Suboptimal antibody dilution

• Cross-reactivity with similar epitopes

• Sample preparation issues

Methodological Solutions:

Validation Strategies:

• Compare results with another CDKN1A antibody targeting a different epitope

• Verify with functional assays (e.g., cell cycle analysis following UV irradiation)

• Use samples with known CDKN1A expression levels (knockdown/overexpression)

Research protocols have successfully employed the CDKN1A (Ab-145) antibody in Western blot analysis of extracts from HeLa cells, with specificity confirmed through peptide competition assays . For enhanced detection sensitivity, protocols have employed signal enhancement systems like "Can Get Signal" to improve antigenic signal detection .

How does CDKN1A phosphorylation status influence experimental outcomes in cancer research models?

CDKN1A phosphorylation status, particularly at threonine 145 (T145), has significant implications for cancer research:

Cellular and Molecular Consequences:

• T145 phosphorylation by activated Akt causes cytoplasmic localization of CDKN1A

• This relocalization can neutralize CDKN1A's nuclear functions in cell cycle control

• Altered CDKN1A localization may contribute to cell cycle dysregulation in cancer cells

Experimental Findings in Cancer Models:

• In ATLL (Adult T-Cell Leukemia/Lymphoma) cell lines, CDKN1A expression is frequently downregulated

• HTLV-1-infected cell lines show phosphorylation-dependent cytoplasmic localization of CDKN1A

• Treatment with PI3K inhibitor LY294002 induces different responses based on cell type:

  • HTLV-1-infected cells: CDKN1A nuclear relocalization and cell cycle arrest

  • ATLL cells: Maintained cytoplasmic localization with apoptosis induction

Methodological Considerations:

• When studying CDKN1A in cancer models, both expression level and phosphorylation status should be assessed

• Subcellular localization should be documented through fractionation or immunofluorescence

• Pathway inhibitors (like LY294002) can be valuable tools to dissect the functional consequences of phosphorylation

Research has shown that low CDKN1A expression in ATLL cells may be a key factor in ATLL leukemogenesis, with abnormal genomic methylation potentially influencing not only HTLV-1 Tax expression but also CDKN1A expression . These findings highlight the complex interplay between viral factors, epigenetic regulation, and post-translational modifications in determining CDKN1A function in cancer cells.

How should researchers quantify and analyze Western blot data using CDKN1A (Ab-145) antibody?

Proper quantification and analysis of Western blot data using CDKN1A (Ab-145) antibody requires rigorous methodological approaches:

Quantification Methods:

• Densitometric analysis of band intensity using software like ImageJ or commercial alternatives

• Normalization to loading controls (β-actin has been used successfully in published protocols)

• Standard curve generation using recombinant protein when absolute quantification is needed

Analysis Approaches:

• For phospho-specific studies, calculate the ratio of phosphorylated to total CDKN1A

• For expression studies, normalize to appropriate housekeeping proteins

• Consider multiple normalization strategies to ensure robustness

Statistical Considerations:

• Perform experiments in at least triplicate for statistical validity

• Use appropriate statistical tests based on data distribution

• Report variance measurements (standard deviation or standard error)

• Consider power analysis to determine sufficient sample size

What are the critical considerations when interpreting conflicting results in CDKN1A localization studies?

When faced with seemingly contradictory results regarding CDKN1A localization:

Common Sources of Discrepancies:

• Cell type-specific responses (as seen in HTLV-1-infected versus ATLL cell lines)

• Varying experimental conditions (fixation methods, antibody specificity)

• Different stress stimuli or treatment durations

• Baseline phosphorylation states of key signaling pathways

Resolution Strategies:

• Methodological Validation:

  • Verify antibody specificity using peptide competition assays

  • Confirm findings with multiple detection methods (IF/ICC, subcellular fractionation)

  • Check cross-reactivity with related proteins

• Biological Context Analysis:

  • Assess activation status of upstream regulators (Akt phosphorylation)

  • Evaluate cell cycle phase distribution of the population

  • Consider p53 status and other CDKN1A regulators

• Integration of Multiple Measurements:

  • Combine localization data with functional readouts (cell cycle analysis, apoptosis)

  • Perform time-course experiments to capture dynamic changes

  • Use pathway inhibitors to establish causal relationships

Research has demonstrated that CDKN1A can have different functions depending on cellular context. For example, following treatment with LY294002, CDKN1A relocalized to the nucleus in HTLV-1-infected cells causing cell cycle arrest, while in ATLL cells, it remained cytoplasmic and induced apoptosis . This contextual difference underscores the importance of considering cell-specific factors when interpreting seemingly conflicting results.

What is the optimal protocol for studying CDKN1A phosphorylation dynamics?

An optimal protocol for investigating CDKN1A phosphorylation dynamics should include:

Cell Culture and Treatment:

• Culture appropriate cell lines (HeLa cells have been validated)

• Design time-course experiments with relevant treatments:

  • PI3K inhibitor LY294002 (20 μM) to inhibit Akt-mediated phosphorylation

  • UV radiation (20 J/m²) to induce DNA damage response

  • Growth factor stimulation (e.g., EGF) to activate Akt signaling

Sample Collection and Processing:

• Harvest cells at multiple timepoints post-treatment

• Include phosphatase inhibitors in all lysis buffers

• Consider separate nuclear and cytoplasmic fractions

• Process samples rapidly at 4°C to preserve phosphorylation states

Detection Methods:

• Western blot analysis using:

  • CDKN1A (Ab-145) antibody for total protein (1:500-1:1000 dilution)

  • Phospho-specific antibody for T145 phosphorylation

  • Antibodies for upstream kinases (total and phospho-Akt)

• Immunofluorescence to visualize subcellular localization:

  • Fix cells with PFA and permeabilize with 0.1% Triton X-100

  • Block in 10% serum for 45 minutes at 25°C

  • Use appropriate dilutions of primary antibodies

  • Employ fluorophore-conjugated secondary antibodies

• Functional assays:

  • Cell cycle analysis by flow cytometry

  • Cell proliferation assays

  • DNA damage repair assessment

Research has shown that in HTLV-1-infected cell lines, activated Akt phosphorylates CDKN1A at T145, leading to cytoplasmic localization. This modification prevents CDKN1A from inhibiting the cell cycle after UV irradiation, but inhibition of PI3K with LY294002 causes dephosphorylation and nuclear relocalization .

How can CDKN1A (Ab-145) antibody be effectively used in multiplex immunofluorescence studies?

For effective multiplex immunofluorescence studies with CDKN1A (Ab-145) antibody:

Optimization Steps:

• Antibody Compatibility Testing:

  • Verify compatible host species for primary antibodies to avoid cross-reactivity

  • Test each antibody individually before multiplexing

  • Validate secondary antibody specificity

• Protocol Development:

  • Sequential staining may be required if antibodies have similar hosts

  • Determine optimal fixation methods (PFA has been validated)

  • Optimize blocking conditions (10% serum for 45 minutes at 25°C has worked well)

• Controls and Validation:

  • Include single-stained controls for each antibody

  • Use spectral controls if employing confocal microscopy

  • Validate with co-localization analysis software

Example Multiplex Protocol:
Based on published approaches, a successful protocol might include:

• Fix cells with PFA and permeabilize in 0.1% Triton X-100

• Block in 10% serum for 45 minutes at 25°C

• Incubate with CDKN1A (Ab-145) antibody (1:200) and other primary antibodies (e.g., anti-beta tubulin at 1:200)

• Use spectrally distinct secondary antibodies (e.g., AlexaFluor594 for CDKN1A, AlexaFluor488 for beta-tubulin)

• Include DAPI as nuclear counterstain

This approach has been successfully employed for dual staining of CDKN1A and beta-tubulin in HepG2 cells treated with LPS, allowing visualization of both proteins simultaneously while maintaining specificity .

How can CDKN1A (Ab-145) antibody contribute to understanding treatment resistance in cancer?

CDKN1A (Ab-145) antibody offers valuable insights into treatment resistance mechanisms:

Research Applications:

• Therapy Response Monitoring:

  • Track CDKN1A expression and localization changes following treatment

  • Correlate phosphorylation status with therapy outcomes

  • Identify predictive biomarkers of response

• Resistance Mechanism Elucidation:

  • Investigate PI3K/Akt pathway activation as a mechanism of resistance

  • Examine CDKN1A subcellular localization in resistant versus sensitive cells

  • Study combinatorial approaches targeting both CDKN1A function and other pathways

• Novel Therapeutic Target Identification:

  • Explore compounds that restore nuclear localization of CDKN1A

  • Investigate synergistic effects of PI3K inhibitors and DNA-damaging agents

  • Develop strategies to normalize CDKN1A function in cancer cells

Methodological Approaches:

• Use paired sensitive/resistant cell lines to identify differential CDKN1A regulation

• Employ PI3K/Akt inhibitors to determine if CDKN1A relocalization restores sensitivity

• Implement CRISPR/Cas9 to generate phospho-mimetic or phospho-deficient CDKN1A mutants

Research has demonstrated that in HTLV-1-infected cells, cytoplasmic CDKN1A fails to inhibit the cell cycle after DNA damage, but inhibition of the PI3K pathway with LY294002 causes CDKN1A dephosphorylation and nuclear relocalization, restoring cell cycle control . This suggests that targeting the pathways regulating CDKN1A phosphorylation could potentially overcome certain forms of treatment resistance.

What are the considerations for developing quantitative assays using CDKN1A (Ab-145) antibody?

Developing robust quantitative assays with CDKN1A (Ab-145) antibody requires:

Assay Design Principles:

• Standardization:

  • Establish recombinant protein standards at known concentrations

  • Develop consistent sample preparation protocols

  • Include internal reference controls in each experiment

• Validation Parameters:

  • Determine linear detection range

  • Assess reproducibility across technical and biological replicates

  • Evaluate sensitivity and specificity using positive and negative controls

• Application-Specific Considerations:

  • For ELISA: Optimize coating, blocking, and detection conditions

  • For Western blot: Standardize loading, transfer, and detection methods

  • For automated image analysis: Develop consistent acquisition parameters

Implementation Strategies:

• Employ statistical methods from experimental research design literature to ensure validity

• Consider randomized control designs to minimize bias

• Implement blinding procedures for analysis when possible

When developing quantitative assays, researchers should follow the principles of experimental design, including proper controls, randomization, and statistical validation . This approach ensures that measurements of CDKN1A expression or phosphorylation are reliable and reproducible across different experimental conditions and laboratory settings.